Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 591703, 17 pages
http://dx.doi.org/10.1155/2014/591703
Review Article

Noncoding RNAs as Novel Biomarkers in Prostate Cancer

1Department of Urology, Radboud University Medical Center, Post 267, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
2Department of Urology, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
3Radboud Institute for Molecular Life Sciences, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

Received 6 June 2014; Accepted 4 August 2014; Published 28 August 2014

Academic Editor: Andreas Doll

Copyright © 2014 C. G. H. Rönnau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Center, A. Jemal, J. Lortet-Tieulent et al., “International variation in prostate cancer incidence and mortality rates,” European Urology, vol. 61, no. 6, pp. 1079–1092, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. W. J. Catalona, D. S. Smith, T. L. Ratliff et al., “Measurement of prostate-specific antigen in serum as a screening test for prostate cancer,” The New England Journal of Medicine, vol. 324, no. 17, pp. 1156–1161, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. F. H. Schröder, J. Hugosson, M. J. Roobol et al., “Screening and prostate-cancer mortality in a randomized european study,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1320–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. L. Andriole, E. D. Crawford, R. L. Grubb III et al., “Mortality results from a randomized prostate-cancer screening trial,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1310–1319, 2009. View at Google Scholar
  6. V. M. Velonas, H. H. Woo, C. G. dos Remedios, and S. J. Assinder, “Current status of biomarkers for prostate cancer,” International Journal of Molecular Sciences, vol. 14, no. 6, pp. 11034–11060, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. E. Oesterling, “Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate,” Journal of Urology, vol. 145, no. 5, pp. 907–923, 1991. View at Google Scholar · View at Scopus
  8. J. Hugosson, S. Carlsson, G. Aus et al., “Mortality results from the Göteborg randomised population-based prostate-cancer screening trial,” The Lancet Oncology, vol. 11, no. 8, pp. 725–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. H. M. Lin, L. Castillo, K. L. Mahon et al., “Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer,” British Journal of Cancer, vol. 110, no. 10, pp. 2462–2471, 2014. View at Publisher · View at Google Scholar
  10. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. C. L. Sawyers, “The cancer biomarker problem,” Nature, vol. 452, no. 7187, pp. 548–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Prensner, M. A. Rubin, J. T. Wei, and A. M. Chinnaiyan, “Beyond PSA: the next generation of prostate cancer biomarkers,” Science Translational Medicine, vol. 4, no. 127, Article ID 127rv3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. B. Gutman and E. B. Gutman, “An acid phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland,” Journal of Clinical Investigation, vol. 17, no. 4, pp. 473–478, 1938. View at Publisher · View at Google Scholar
  15. Y. Liu, P. Hegde, F. Zhang, G. Hampton, and S. Jia, “Prostate cancer—a biomarker perspective,” Frontiers in Endocrinology, vol. 3, article 72, Article ID Article 72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Dijkstra, P. F. Mulders, and J. A. Schalken, “Clinical use of novel urine and blood based prostate cancer biomarkers: a review,” Clinical Biochemistry, vol. 47, no. 10-11, pp. 889–896, 2014. View at Publisher · View at Google Scholar
  17. R. Kuner, J. C. Brase, H. Sültmann, and D. Wuttig, “MicroRNA biomarkers in body fluids of prostate cancer patients,” Methods, vol. 59, no. 1, pp. 132–137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Hessels and J. A. Schalken, “Urinary biomarkers for prostate cancer: a review,” Asian Journal of Andrology, vol. 15, no. 3, pp. 333–339, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. P. K. Singh and M. J. Campbell, “The interactions of microRNA and epigenetic modifications in prostate cancer,” Cancers, vol. 5, no. 3, pp. 998–1019, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Li, H. Zhang, X. Wan et al., “Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma,” BioMed Research International, vol. 2014, Article ID 780521, 8 pages, 2014. View at Publisher · View at Google Scholar
  21. E. Birney, J. A. Stamatoyannopoulos, A. Dutta et al., “Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project,” Nature, vol. 7146, pp. 799–816, 2007. View at Google Scholar
  22. E. M. Bolton, A. V. Tuzova, A. L. Walsh, T. Lynch, and A. S. Perry, “Noncoding RNAs in prostate cancer: the long and the short of it,” Clinical Cancer Research, vol. 20, no. 1, pp. 35–43, 2014. View at Google Scholar
  23. A. L. Walsh, A. V. Tuzova, E. M. Bolton, T. H. Lynch, and A. S. Perry, “Long noncoding RNAs and prostate carcinogenesis: the missing “linc”?” Trends in Molecular Medicine, vol. 20, no. 8, pp. 428–436, 2014. View at Publisher · View at Google Scholar
  24. R. Kurokawa, “Long noncoding RNA as a regulator for transcription,” Progress in Molecular and Subcellular Biology, vol. 51, pp. 29–41, 2011. View at Google Scholar
  25. T. Hung and H. Y. Chang, “Long noncoding RNA in genome regulation: prospects and mechanisms,” RNA Biology, vol. 7, no. 5, pp. 582–585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. E. Wilusz, H. Sunwoo, and D. L. Spector, “Long noncoding RNAs: functional surprises from the RNA world,” Genes and Development, vol. 23, no. 13, pp. 1494–1504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Kim and S. Sung, “Long noncoding RNA: unveiling hidden layer of gene regulatory networks,” Trends in Plant Science, vol. 17, no. 1, pp. 16–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. H. Yoon, K. Abdelmohsen, and M. Gorospe, “Posttranscriptional gene regulation by long noncoding RNA,” Journal of Molecular Biology, vol. 425, no. 19, pp. 3723–3730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Kozomara and S. Griffiths-Jones, “MiRBase: integrating microRNA annotation and deep-sequencing data,” Nucleic Acids Research, vol. 39, no. 1, pp. D152–D157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. V. N. Kim, “MicroRNA biogenesis: coordinated cropping and dicing,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376–385, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Schwarzenbach, N. Nishida, G. A. Calin, and Pantel K, “Clinical relevance of circulating cell-free microRNAs in cancer,” Nature Reviews Clinical Oncology, vol. 11, no. 3, pp. 145–156, 2014. View at Google Scholar
  32. J. Krol, I. Loedige, and W. Filipowicz, “The widespread regulation of microRNA biogenesis, function and decay,” Nature Reviews Genetics, vol. 11, no. 9, pp. 597–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Croce, “Causes and consequences of microRNA dysregulation in cancer,” Nature Reviews Genetics, vol. 10, no. 10, pp. 704–714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Chen, “MicroRNAs as oncogenes and tumor suppressors,” The New England Journal of Medicine, vol. 353, no. 17, pp. 1768–1771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Brameier, A. Herwig, R. Reinhardt, L. Walter, and J. Gruber, “Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs,” Nucleic Acids Research, vol. 39, no. 2, pp. 675–686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. E. S. Martens-Uzunova, M. Olvedy, and G. Jenster, “Beyond microRNA—novel RNAs derived from small non-coding RNA and their implication in cancer,” Cancer Letters, vol. 340, no. 2, pp. 201–211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Su, T. Xu, S. Ganapathy et al., “Elevated snoRNA biogenesis is essential in breast cancer,” Oncogene, vol. 33, no. 11, pp. 1348–1358, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Liao, L. Yu, Y. Mei et al., “Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer,” Molecular Cancer, vol. 9, article 198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. J. B. De Kok, G. W. Verhaegh, R. W. Roelofs et al., “DD3PCA3, a very sensitive and specific marker to detect prostate tumors,” Cancer Research, vol. 62, no. 9, pp. 2695–2698, 2002. View at Google Scholar · View at Scopus
  41. D. Hessels, J. M. Klein Gunnewiek, I. van Oort et al., “DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer,” European Urology, vol. 44, no. 1, pp. 8–15, 2003. View at Google Scholar
  42. M. P. M. Q. Van Gils, D. Hessels, O. Van Hooij et al., “The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance,” Clinical Cancer Research, vol. 13, no. 3, pp. 939–943, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Hessels and J. A. Schalken, “The use of PCA3 in the diagnosis of prostate cancer,” Nature Reviews Urology, vol. 6, no. 5, pp. 255–261, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Ren, Y. Liu, W. Xu et al., “Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer,” The Journal of Urology, vol. 190, no. 6, pp. 2278–2287, 2013. View at Publisher · View at Google Scholar
  45. W. Prensner Chen Jr., MK. Iyer, Q. Cao et al., “PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer,” Cancer Research, vol. 74, no. 6, pp. 1651–1660, 2014. View at Google Scholar
  46. J. R. Prensner, M. K. Iyer, A. Sahu et al., “The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex,” Nature Genetics, vol. 45, no. 11, pp. 1392–1398, 2013. View at Publisher · View at Google Scholar
  47. V. Srikantan, Z. Zou, G. Petrovics et al., “PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12216–12221, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Yang, C. Lin, C. Jin et al., “LncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs,” Nature, vol. 500, no. 7464, pp. 598–602, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. R. Prensner, A. Sahu, M. K. Iyer et al., “The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer,” Oncotarget, vol. 5, no. 6, pp. 1434–1438, 2014. View at Google Scholar
  50. F. Crea, A. Watahiki, L. Quagliata et al., “Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer,” Oncotarget, vol. 5, no. 3, pp. 764–774, 2014. View at Google Scholar
  51. Z. Cui, S. Ren, J. Lu et al., “The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 7, pp. 1117–1123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. B. A. Walter, V. A. Valera, P. A. Pinto, and M. J. Merino, “Comprehensive microRNA profiling of prostate cancer,” Journal of Cancer, vol. 4, no. 5, pp. 350–357, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Garzon, G. Marcucci, and C. M. Croce, “Targeting microRNAs in cancer: rationale, strategies and challenges,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 775–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Q. Zhang, H. Sun, R. Zheng et al., “Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues,” Gene, vol. 527, no. 1, pp. 26–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Volinia, G. A. Calin, C. Liu et al., “A microRNA expression signature of human solid tumors defines cancer gene targets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2257–2261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Kumarswamy, I. Volkmann, and T. Thum, “Regulation and function of miRNA-21 in health and disease,” RNA Biology, vol. 8, no. 5, pp. 706–713, 2011. View at Google Scholar · View at Scopus
  57. F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T. Jacob, and T. Patel, “MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer,” Gastroenterology, vol. 133, no. 2, pp. 647–658, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. L. B. Frankel, N. R. Christoffersen, A. Jacobsen, M. Lindow, A. Krogh, and A. H. Lund, “Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells,” The Journal of Biological Chemistry, vol. 283, no. 2, pp. 1026–1033, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Zhu, M. Si, H. Wu, and Y. Mo, “MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1),” The Journal of Biological Chemistry, vol. 282, no. 19, pp. 14328–14336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. Z. Zhang, Z. Li, C. Gao et al., “miR-21 plays a pivotal role in gastric cancer pathogenesis and progression,” Laboratory Investigation, vol. 88, no. 12, pp. 1358–1366, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Wang and Q. Zhang, “The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 10, pp. 1659–1666, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Abraham, N. Jackson, J. S. Gundara et al., “MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets,” Clinical Cancer Research, vol. 17, no. 14, pp. 4772–4781, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Lin, J. Sun, J. Wu et al., “Aberrant microRNAs expression in CD133+/CD326+ human lung adenocarcinoma initiating cells from A549,” Molecules and Cells, vol. 33, no. 3, pp. 277–283, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Xu, Z. Dong, Y. Li et al., “The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 3, pp. 536–545, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. B. L. Mihelich, E. A. Khramtsova, N. Arva et al., “MiR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells,” The Journal of Biological Chemistry, vol. 286, no. 52, pp. 44503–44511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Schaefer, M. Jung, H.-J. Mollenkopf et al., “Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma,” International Journal of Cancer, vol. 126, no. 5, pp. 1166–1176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Tsuchiyama, H. Ito, M. Taga et al., “Expression of MicroRNAs associated with Gleason grading system in prostate cancer: MiR-182-5p is a useful marker for high grade prostate cancer,” Prostate, vol. 73, no. 8, pp. 827–834, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. O. Larne, E. Martens-Uzunova, Z. Hagman et al., “MiQ—a novel microRNA based diagnostic and prognostic tool for prostate cancer,” International Journal of Cancer, vol. 132, no. 12, pp. 2867–2875, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Zhu, Y. Feng, Z. Ke et al., “Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin,” The American Journal of Pathology, vol. 180, no. 6, pp. 2440–2451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Hanke, K. Hoefig, H. Merz et al., “A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer,” Urologic Oncology, vol. 28, no. 6, pp. 655–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Yamada, H. Enokida, S. Kojima et al., “MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology,” Cancer Science, vol. 102, no. 3, pp. 522–529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Sun, X. Wang, H. H. He et al., “MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A,” Oncogene, vol. 33, no. 21, pp. 2790–2800, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. F. Hong, Y. Li, Y. Xu, and L. Zhu, “Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer,” Journal of International Medical Research, vol. 41, no. 1, pp. 64–71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. S. X. Hou, B. J. Ding, H. Z. Li et al., “Identification of microRNA-205 as a potential prognostic indicator for human glioma,” Journal of Clinical Neuroscience, vol. 20, no. 7, pp. 933–937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. X. Yue, P. Wang, J. Xu et al., “MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A,” Oncology Reports, vol. 27, no. 4, pp. 1200–1206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Liu, M. T. Tetzlaff, A. Liu, B. Liegl-Atzwanger, J. Guo, and X. Xu, “Loss of microRNA-205 expression is associated with melanoma progression,” Laboratory Investigation, vol. 92, no. 7, pp. 1084–1096, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Adachi, S. Horiuchi, Y. Sakurazawa, T. Hasegawa, K. Sato, and T. Sakamaki, “ErbB2 down-regulates microRNA-205 in breast cancer,” Biochemical and Biophysical Research Communications, vol. 411, no. 4, pp. 804–808, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. V. Iorio, P. Casalini, C. Piovan et al., “MicroRNA-205 regulates HER3 in human breast cancer,” Cancer Research, vol. 69, no. 6, pp. 2195–2200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Majid, S. Saini, A. A. Dar et al., “MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer,” Cancer Research, vol. 71, no. 7, pp. 2611–2621, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Majid, A. A. Dar, S. Saini et al., “MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer,” Cancer, vol. 116, no. 24, pp. 5637–5649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Verdoodt, M. Neid, M. Vogt et al., “MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer,” International Journal of Oncology, vol. 43, no. 1, pp. 307–314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Tucci, M. Agostini, F. Grespi et al., “Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 38, pp. 15312–15317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Hulf, T. Sibbritt, E. D. Wiklund et al., “Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer,” Oncogene, vol. 32, no. 23, pp. 2891–2899, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. P. Gandellini, M. Folini, N. Longoni et al., “MiR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cε,” Cancer Research, vol. 69, no. 6, pp. 2287–2295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. Z. Hagman, B. S. Haflidadóttir, J. A. Ceder et al., “MiR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients,” The British Journal of Cancer, vol. 108, no. 8, pp. 1668–1676, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. P. A. Gregory, C. P. Bracken, A. G. Bert, and G. J. Goodall, “MicroRNAs as regulators of epithelial-mesenchymal transition,” Cell Cycle, vol. 7, no. 20, pp. 3112–3117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Song, Y. Li, J. Lee, A. L. Schwartz, and G. Bu, “Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9,” Cancer Research, vol. 69, no. 3, pp. 879–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Song and G. Bu, “MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1,” Biochemical and Biophysical Research Communications, vol. 388, no. 2, pp. 400–405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Wang, Q. Li, N. H. Feng et al., “miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth,” Asian Journal of Andrology, vol. 15, no. 6, pp. 735–741, 2013. View at Google Scholar
  90. J. Liu, Q. Mao, Y. Liu, X. Hao, S. Zhang, and J. Zhang, “Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients,” Chinese Journal of Cancer Research, vol. 25, no. 1, pp. 46–54, 2013. View at Publisher · View at Google Scholar
  91. E. S. Martens-Uzunova, S. E. Jalava, N. F. Dits et al., “Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer,” Oncogene, vol. 31, no. 8, pp. 978–991, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. J. I. Santos, AL. Teixeira, F. Dias et al., “Restoring TGFbeta1 pathway-related microRNAs: possible impact in metastatic prostate cancer development,” Tumour Biology, vol. 35, no. 7, pp. 6245–6253, 2014. View at Publisher · View at Google Scholar
  93. B. N. Davis-Dusenbery, M. C. Chan, K. E. Reno et al., “Down-regulation of Krüppel-like Factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-β and bone morphogenetic protein 4,” The Journal of Biological Chemistry, vol. 286, no. 32, pp. 28097–28110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. J. Tammela, and T. Visakorpi, “MicroRNA expression profiling in prostate cancer,” Cancer Research, vol. 67, no. 13, pp. 6130–6135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Ambs, R. L. Prueitt, M. Yi et al., “Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer,” Cancer Research, vol. 68, no. 15, pp. 6162–6170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Ozen, C. J. Creighton, M. Ozdemir, and M. Ittmann, “Widespread deregulation of microRNA expression in human prostate cancer,” Oncogene, vol. 27, no. 12, pp. 1788–1793, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. A. W. Tong, P. Fulgham, C. Jay et al., “MicroRNA profile analysis of human prostate cancers,” Cancer Gene Therapy, vol. 16, no. 3, pp. 206–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Spahn, S. Kneitz, C. Scholz et al., “Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence,” International Journal of Cancer, vol. 127, no. 2, pp. 394–403, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. M. A. Cortez, C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A. K. Sood, and G. A. Calin, “MicroRNAs in body fluids-the mix of hormones and biomarkers,” Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 467–477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513–10518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. X. Chen, Y. Ba, L. Ma et al., “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases,” Cell Research, vol. 18, no. 10, pp. 997–1006, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, “MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins,” Nature Cell Biology, vol. 13, no. 4, pp. 423–435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Gallo, M. Tandon, I. Alevizos, and G. G. Illei, “The majority of microRNAs detectable in serum and saliva is concentrated in exosomes,” PLoS ONE, vol. 7, no. 3, Article ID e30679, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. X. Huang, T. Yuan, M. Tschannen et al., “Characterization of human plasma-derived exosomal RNAs by deep sequencing,” BMC Genomics, vol. 14, no. 1, article 319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Y. Ha, “The role of MicroRNAs in regulatory T cells and in the immune response,” Immune Network, vol. 11, no. 1, pp. 11–41, 2011. View at Google Scholar
  107. S. Toffanin, D. Sia, and A. Villanueva, “MicroRNAs: new ways to block tumor angiogenesis?” Journal of Hepatology, vol. 57, no. 3, pp. 490–491, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Ribas, X. Ni, M. Haffner et al., “MiR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth,” Cancer Research, vol. 69, no. 18, pp. 7165–7169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. H. C. N. Nguyen, W. Xie, M. Yang et al., “Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer,” Prostate, vol. 73, no. 4, pp. 346–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. H. L. Zhang, L. F. Yang, Y. Zhu et al., “Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy,” Prostate, vol. 71, no. 3, pp. 326–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. H. H. Cheng, P. S. Mitchell, E. M. Kroh et al., “Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia,” PLoS ONE, vol. 8, no. 7, Article ID e69239, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. R. J. Bryant, T. Pawlowski, J. W. F. Catto et al., “Changes in circulating microRNA levels associated with prostate cancer,” British Journal of Cancer, vol. 106, no. 4, pp. 768–774, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. J. C. Brase, M. Johannes, T. Schlomm et al., “Circulating miRNAs are correlated with tumor progression in prostate cancer,” International Journal of Cancer, vol. 128, no. 3, pp. 608–616, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. H. Okada, G. Kohanbash, and M. T. Lotze, “MicroRNAs in immune regulation-opportunities for cancer immunotherapy,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 8, pp. 1256–1261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. F. Y. Agaoglu, M. Kovancilar, Y. Dizdar et al., “Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer,” Tumor Biology, vol. 32, no. 3, pp. 583–588, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Shen, G. W. Hruby, J. M. McKiernan et al., “Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer,” Prostate, vol. 72, no. 13, pp. 1469–1477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. L. A. Selth, S. Townley, J. L. Gillis et al., “Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease,” International Journal of Cancer, vol. 131, no. 3, pp. 652–661, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J. C. Gonzales, L. M. Fink, O. B. Goodman Jr., J. T. Symanowski, N. J. Vogelzang, and D. C. Ward, “Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer,” Clinical Genitourinary Cancer, vol. 9, no. 1, pp. 39–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. L. A. Selth, S. L. Townley, A. G. Bert et al., “Circulating microRNAs predict biochemical recurrence in prostate cancer patients,” British Journal of Cancer, vol. 109, no. 3, pp. 641–650, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. A. M. Westermann, D. Schmidt, S. Holdenrieder et al., “Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study,” Anticancer Research, vol. 34, no. 2, pp. 665–669, 2014. View at Google Scholar
  121. K. K. Waltering, K. P. Porkka, S. E. Jalava et al., “Androgen regulation of micro-RNAs in prostate cancer,” Prostate, vol. 71, no. 6, pp. 604–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. D. Tiryakioglu, E. Bilgin, S. Holdenrieder, N. Dalay, and U. Gezer, “miR-141 and miR-375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells,” Biomedical Reports, vol. 1, no. 5, pp. 802–806, 2013. View at Google Scholar
  123. R. B. Montgomery, E. A. Mostaghel, R. Vessella et al., “Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth,” Cancer Research, vol. 68, no. 11, pp. 4447–4454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. Z. H. Chen, G. L. Zhang, H. Li et al., “A panel of five circulating microRNAs as potential biomarkers for prostate cancer,” Prostate, vol. 72, no. 13, pp. 1443–1452, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. N. P. Hessvik, K. Sandvig, and A. Llorente, “Exosomal miRNAs as biomarkers for prostate cancer,” Frontiers in Genetics, vol. 4, article 36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. H. M. Heneghan, N. Miller, R. Kelly, J. Newell, and M. J. Kerin, “Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease,” Oncologist, vol. 15, no. 7, pp. 673–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. R. Mahn, L. C. Heukamp, S. Rogenhofer, A. Von Ruecker, S. C. Müller, and J. Ellinger, “Circulating microRNAs (miRNA) in serum of patients with prostate cancer,” Urology, vol. 77, no. 5, pp. 1265.e9–1265.e16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. M. J. Lodes, M. Caraballo, D. Suciu, S. Munro, A. Kumar, and B. Anderson, “Detection of cancer with serum miRNAs on an oligonucleotide microarray,” PLoS ONE, vol. 4, no. 7, Article ID e6229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. F. Moltzahn, A. B. Olshen, L. Baehner et al., “Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients,” Cancer Research, vol. 71, no. 2, pp. 550–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Srivastava, H. Goldberger, A. Dimtchev et al., “Circulatory miR-628-5p is downregulated in prostate cancer patients,” Tumor Biology, vol. 35, no. 5, pp. 4867–4873, 2014. View at Publisher · View at Google Scholar
  131. A. Sita-Lumsden, D. A. Dart, J. Waxman, and C. L. Bevan, “Circulating microRNAs as potential new biomarkers for prostate cancer,” The British Journal of Cancer, vol. 108, no. 10, pp. 1925–1930, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. E. M. Kroh, R. K. Parkin, P. S. Mitchell, and M. Tewari, “Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR),” Methods, vol. 50, no. 4, pp. 298–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. X. Huang, M. Liang, R. Dittmar, and L. Wang, “Extracellular microRNAs in urologic malignancies: chances and challenges,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14785–14799, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. A. Srivastava, H. Goldberger, A. Dimtchev et al., “MicroRNA profiling in prostate cancer—the diagnostic potential of urinary miR-205 and miR-214,” PLoS ONE, vol. 8, no. 10, Article ID e76994, 2013. View at Publisher · View at Google Scholar
  135. T. A. Haj-Ahmad, M. A. Abdalla, and Y. Haj-Ahmad, “Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients,” Journal of Cancer, vol. 5, no. 3, pp. 182–191, 2014. View at Publisher · View at Google Scholar
  136. N. Sapre, M. K. Hong, G. Macintyre et al., “Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer,” PLoS One, vol. 9, no. 4, Article ID e91729, 2014. View at Google Scholar
  137. J. I. Santos, A. L. Teixeira, F. Dias et al., “Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies,” Tumor Biology, vol. 35, no. 7, pp. 7105–7113, 2014. View at Publisher · View at Google Scholar
  138. B. Kneitz, M. Krebs, C. Kalogirou et al., “Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3,” Cancer Research, vol. 74, no. 9, pp. 2591–2603, 2014. View at Google Scholar
  139. S. P. Huang, E. Levesque, C. Guillemette et al., “Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  140. K. R. Kutanzi, O. V. Yurchenko, F. A. Beland, V. F. Checkhun, and I. P. Pogribny, “MicroRNA-mediated drug resistance in breast cancer,” Clinical Epigenetics, vol. 2, no. 2, pp. 171–185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. A. Lujambio and S. W. Lowe, “The microcosmos of cancer,” Nature, vol. 482, no. 7385, pp. 347–355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. I. Giusti and V. Dolo, “Extracellular vesicles in prostate cancer: new future clinical strategies?” BioMed Research International, vol. 2014, Article ID 561571, 14 pages, 2014. View at Publisher · View at Google Scholar
  143. S. Mathivanan, H. Ji, and R. J. Simpson, “Exosomes: extracellular organelles important in intercellular communication,” Journal of Proteomics, vol. 73, no. 10, pp. 1907–1920, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. B. György, K. Módos, É. Pállinger et al., “Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters,” Blood, vol. 117, no. 4, pp. e39–e48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. I. Nazarenko, S. Rana, A. Baumann et al., “Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation,” Cancer Research, vol. 70, no. 4, pp. 1668–1678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. T. Kogure, W. L. Lin, I. K. Yan, C. Braconi, and T. Patel, “Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth,” Hepatology, vol. 54, no. 4, pp. 1237–1248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. C. Grange, M. Tapparo, F. Collino et al., “Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche,” Cancer Research, vol. 71, no. 15, pp. 5346–5356, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. S. L. Wood, M. A. Knowles, D. Thompson, P. J. Selby, and R. E. Banks, “Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers,” Nature Reviews Urology, vol. 10, no. 4, pp. 206–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Delcayre, H. Shu, and J. Le Pecq, “Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway,” Expert Review of Anticancer Therapy, vol. 5, no. 3, pp. 537–547, 2005. View at Publisher · View at Google Scholar · View at Scopus
  150. C. Théry, M. Boussac, P. Véron et al., “Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles,” The Journal of Immunology, vol. 166, no. 12, pp. 7309–7318, 2001. View at Publisher · View at Google Scholar · View at Scopus
  151. F. F. van Doormaal, A. Kleinjan, M. di Nisio, H. R. Büller, and R. Nieuwland, “Cell-derived microvesicles and cancer,” Netherlands Journal of Medicine, vol. 67, no. 7, pp. 266–273, 2009. View at Google Scholar · View at Scopus
  152. M. A. Antonyak, B. Li, L. K. Boroughs et al., “Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4852–4857, 2011. View at Publisher · View at Google Scholar · View at Scopus
  153. K. Shedden, X. T. Xie, P. Chandaroy, Y. T. Chang, and G. R. Rosania, “Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles,” Cancer Research, vol. 63, no. 15, pp. 4331–4337, 2003. View at Google Scholar · View at Scopus
  154. D. Duijvesz, T. Luider, C. H. Bangma, and G. Jenster, “Exosomes as biomarker treasure chests for prostate cancer,” European Urology, vol. 59, no. 5, pp. 823–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. G. Ronquist and I. Brody, “The prostasome: its secretion and function in man,” Biochimica et Biophysica Acta, vol. 822, no. 2, pp. 203–218, 1985. View at Publisher · View at Google Scholar · View at Scopus
  156. G. Ronquist, “Prostasomes are mediators of intercellular communication: from basic research to clinical implications,” Journal of Internal Medicine, vol. 271, no. 4, pp. 400–413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  157. G. Tavoosidana, G. Ronquist, S. Darmanis et al., “Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 21, pp. 8809–8814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. A. Beach, H. G. Zhang, M. Z. Ratajczak, and S. S. Kakar, “Exosomes: an overview of biogenesis, composition and role in ovarian cancer,” Journal of Ovarian Research, vol. 7, article 14, 2014. View at Google Scholar
  159. D. D. Taylor and C. Gercel-Taylor, “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer,” Gynecologic Oncology, vol. 110, no. 1, pp. 13–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. G. Rabinowits, C. Gerçel-Taylor, J. M. Day, D. D. Taylor, and G. H. Kloecker, “Exosomal microRNA: a diagnostic marker for lung cancer,” Clinical Lung Cancer, vol. 10, no. 1, pp. 42–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. W. T. Kim and W. J. Kim, “MicroRNAs in prostate cancer,” Prostate International, vol. 1, no. 1, pp. 3–9, 2013. View at Google Scholar
  162. C. Soekmadji, P. J. Russell, and C. C. Nelson, “Exosomes in prostate cancer: putting together the pieces of a puzzle,” Cancers, vol. 5, no. 4, pp. 1522–1544, 2013. View at Publisher · View at Google Scholar
  163. F. H. Jansen, J. Krijgsveld, A. van Rijswijk et al., “Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins,” Molecular and Cellular Proteomics, vol. 8, no. 6, pp. 1192–1205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  164. J. Nilsson, J. Skog, A. Nordstrand et al., “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer,” The British Journal of Cancer, vol. 100, no. 10, pp. 1603–1607, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. E. S. Lianidou, A. Strati, and A. Markou, “Circulating tumor cells as promising novel biomarkers in solid cancers,” Critical Reviews in Clinical Laboratory Sciences, vol. 51, no. 3, pp. 160–171, 2014. View at Google Scholar
  166. J. S. de Bono, H. I. Scher, R. B. Montgomery et al., “Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 14, no. 19, pp. 6302–6309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. D. Olmos, H. T. Arkenau, J. E. Ang et al., “Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience,” Annals of Oncology, vol. 20, no. 1, pp. 27–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. H. I. Scher, X. Jia, J. S. de Bono et al., “Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data,” The Lancet Oncology, vol. 10, no. 3, pp. 233–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  169. D. C. Danila, M. Fleisher, and H. I. Scher, “Circulating tumor cells as biomarkers in prostate cancer,” Clinical Cancer Research, vol. 17, no. 12, pp. 3903–3912, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. A. M. Sieuwerts, B. Mostert, J. Bolt-De Vries et al., “mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients,” Clinical Cancer Research, vol. 17, no. 11, pp. 3600–3618, 2011. View at Publisher · View at Google Scholar · View at Scopus